Last reviewed 2026-05-22 · How we verify

Topical AFX5931

The Center for Clinical and Cosmetic Research · FDA-approved active Small molecule Under review

Topical AFX5931 is a Small molecule drug developed by The Center for Clinical and Cosmetic Research. It is currently FDA-approved for Dermatological or cosmetic indication (specific indication not publicly documented).

AFX5931 is a topical formulation designed to modulate skin inflammation and promote wound healing or tissue repair through its active pharmaceutical ingredient.

Topical AFX5931 is being studied as a potential treatment for hand dermatitis in a clinical trial. The mechanism of action of Topical AFX5931 is currently unknown.

At a glance

Generic name	Topical AFX5931
Sponsor	The Center for Clinical and Cosmetic Research
Modality	Small molecule
Therapeutic area	Dermatology
Phase	FDA-approved

Mechanism of action

Without publicly available detailed mechanism information, AFX5931 appears to be a topical therapeutic agent developed for dermatological or cosmetic applications. The specific molecular target and precise mechanism of action are not clearly documented in standard pharmaceutical databases, suggesting this may be a proprietary or early-stage marketed product with limited public disclosure.

Approved indications

Dermatological or cosmetic indication (specific indication not publicly documented)

Common side effects

No common side effects on file.

Key clinical trials

A Study for a Topical Medication Versus Placebo in Patients With Hand Dermatitis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Topical AFX5931 CI brief — competitive landscape report
Topical AFX5931 updates RSS · CI watch RSS
The Center for Clinical and Cosmetic Research portfolio CI

Frequently asked questions about Topical AFX5931

What is Topical AFX5931?

Topical AFX5931 is a Small molecule drug developed by The Center for Clinical and Cosmetic Research, indicated for Dermatological or cosmetic indication (specific indication not publicly documented).

How does Topical AFX5931 work?

AFX5931 is a topical formulation designed to modulate skin inflammation and promote wound healing or tissue repair through its active pharmaceutical ingredient.

What is Topical AFX5931 used for?

Topical AFX5931 is indicated for Dermatological or cosmetic indication (specific indication not publicly documented).

Who makes Topical AFX5931?

Topical AFX5931 is developed and marketed by The Center for Clinical and Cosmetic Research (see full The Center for Clinical and Cosmetic Research pipeline at /company/the-center-for-clinical-and-cosmetic-research).

What development phase is Topical AFX5931 in?

Topical AFX5931 is FDA-approved (marketed).

Manufacturer: The Center for Clinical and Cosmetic Research — full pipeline
Therapeutic area: All drugs in Dermatology
Indication: Drugs for Dermatological or cosmetic indication (specific indication not publicly documented)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing